Threshold Pharmaceuticals Inc., of South San Francisco, said the independent data monitoring committee completed the planned interim efficacy and safety analyses of unblinded data for the firm's pivotal phase III trial of TH-302 in combination with doxorubicin vs. doxorubicin alone in patients with locally advanced unresectable or metastatic soft-tissue sarcoma.